Novo Nordisk A/S Common Stock (NVO)

Energy drinks face negative publicity and competition, leading to sell-offs in Monster and Celsius. Increasing foot traffic may offer hope for a recovery.

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.

Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.

Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (“FDA”) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer’s. However, there is no molecule or a combination of molecules that enhance cognitive functions. Thanks to innovative approaches by companies such as Annovis Bio Inc. (NYSEANVS) ( profile ), there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications. Broadly speaking, there is ample reason to be bullish on new treatments for a variety of significant diseases, including AD and obesity, as companies such as Eli Lilly NYSE: LLYNYSELLY)(NYSE: PFENYSEPFE , Novo Nordisk (NYSE: NVONYSE) and AbbVie Inc. (NASDAQ: ABBVABBV) are making investments and progress on historically…

EQNX::TICKER_START (NYSEANVS),NYSE:LLYNYSELLY)(NYSE:PFENYSEPFE,(NYSE:NVONYSE),(NASDAQ:ABBVABBV) EQNX::TICKER_END

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.

The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit.

Viking Therapeutics Inc. (NASDAQVKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market.

Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?

Eli Lilly and Co. (NYSELLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.

Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings

Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide.

Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in.

Annovis Bio (NYSEANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity[R]) in enhancing cognition in a mouse model of Alzheimer’s disease.

Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.

EQNX::TICKER_START (NYSEANVS),NYSE:PFENYSEPFE)(NYSE:LLYNYSELLY,(NYSE:GSKNYSE),(NYSE:NVONVO) EQNX::TICKER_END

PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The growth of the Alzheimer's Disease Therapeutics Market is directly influenced by the increasing prevalence of Alzheimer's disease globally. The higher incidence of this neurodegenerative disorder has significantly elevated the demand for therapeutic solutions. Alzheimer's is characterized as a chronic brain condition that frequently results in dementia, particularly in older individuals. It adversely affects memory, cognitive function, and disrupts daily routines. Advanced age is a significant factor in increasing the likelihood of developing this condition… Other risk factors involve cardiovascular disease, high blood pressure, diabetes, stroke, and conditions related to vascular health. Notably, there is no singular test for diagnosing Alzheimer's disease. The global Alzheimer's Disease Therapeutics Market is witnessing robust growth driven by a combination of factors. The escalating aging population, particularly in developed nations, is contributing to a rising prevalence of Alzheimer's disease. Advances in diagnostic tools, neuroimaging, and molecular biomarkers are enabling earlier and more accurate diagnosis, facilitating timely interventions. Immunotherapy, such as Aducanumab, and the exploration of various drug classes like cholinesterase inhibitors and NMDA receptor antagonists, signify an evolving landscape in therapeutic approaches.   Active biotech, pharma companies in the markets this week include: Annovis Bio Inc. (NYSEANVS) (ANVS Profile), Pfizer Inc. NYSE: PFENYSEPFE)(NYSE: LLYNYSELLY, GSK plc (NYSE: GSKNYSE), Novo Nordisk A/S (NYSE: NVONVO).

Global pharmaceutical company Eli Lilly & Co. (NYSELLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been

The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season

Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases

Pharmaceutical giant Pfizer Inc. (NYSEPFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy